Cannabis Bioactive Compound-Based Formulations: New Perspectives for the Management of Orofacial Pain

Molecules. 2022 Dec 23;28(1):106. doi: 10.3390/molecules28010106.


The management of orofacial pain to alleviate the quality of life of affected patients is becoming increasingly challenging for scientific research and healthcare professionals. From this perspective, in addition to conventional therapies, new alternatives are being sought, increasingly looking at the use of both natural and synthetic products. Cannabis sativa L. represents an interesting source of bioactive compounds, including non-psychoactive cannabinoids, flavonoids, and terpenes, many of which are effective in improving pain intensity. Here, we aim to analyze the possible mechanisms of action of the bioactive natural and synthetic hemp-derived compounds responsible for the modulatory effects on pain-related pathways. The ability of these compounds to act on multiple mechanisms through a synergistic effect, reducing both the release of inflammatory mediators and regulating the response of the endocannabinoid system, makes them interesting agents for alternative formulations to be used in orofacial pain.

Keywords: Cannabis sativa L.; cannabinoids; inflammation; orofacial pain; temporomandibular disorders; terpenes.

Publication types

  • Review

MeSH terms

  • Cannabinoid Receptor Agonists
  • Cannabinoids* / pharmacology
  • Cannabinoids* / therapeutic use
  • Cannabis*
  • Facial Pain / drug therapy
  • Hallucinogens*
  • Humans
  • Quality of Life


  • Cannabinoids
  • Hallucinogens
  • Cannabinoid Receptor Agonists

Grants and funding

This research received no external funding.